saroglitazar

a PPARalpha and PPARgamma agonist

Also Known As:

(2S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylsulfanyl)phenyl)-1H-pyrrol-1-yl(ethoxy)phenyl)propanoic acid; (2S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylsulfanyl)phenyl)-1H-pyrrol-1-yl(ethoxy)phenyl)propanoic acid magnesium salt (2:1); Lipaglyn; ZYH1 compound; alpha-ethoxy-4-(2-(2-methyl-5-(4-methylthio)phenyl))-1H-pyrrol-1-yl)ethoxy))benzenepropanoic acid; alpha-ethoxy-4-(2-(2-methyl-5-(4-methylthio)phenyl))-1H-pyrrol-1-yl)ethoxy))benzenepropanoic acid magnesium salt; saroglitazar magnesium

Networked: 67 relevant articles (28 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Parmar, Deven: 6 articles (01/2022 - 01/2019)
2.	Jain, Mukul R: 4 articles (01/2020 - 06/2015)
3.	Shaikh, Farheen: 3 articles (01/2022 - 01/2021)
4.	Patel, Pankaj: 3 articles (10/2021 - 01/2014)
5.	Parmar, Krupi: 3 articles (07/2020 - 01/2019)
6.	Giri, Suresh R: 3 articles (01/2020 - 06/2015)
7.	Bhansali, Anil: 3 articles (12/2019 - 01/2014)
8.	Jani, Rajendrakumar H: 3 articles (01/2016 - 01/2014)
9.	Joshi, Shashank: 3 articles (01/2016 - 01/2014)
10.	Parmar, Deven V: 2 articles (01/2022 - 07/2020)

Related Diseases

1.	Dyslipidemias (Dyslipidemia) 07/01/2020 - "The saroglitazar treatment significantly improved postprandial TGs in people with diabetic dyslipidemia. " 06/01/2015 - "Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes. " 01/01/2015 - "Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients." 01/01/2022 - "Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies." 07/01/2020 - "This was a 12-week, prospective, multicenter, randomized, double-blinded, placebo-controlled study of saroglitazar in patients with diabetes and dyslipidemia. "
2.	Non-alcoholic Fatty Liver Disease 01/01/2023 - "In the present study, we evaluated the safety and efficacy of saroglitazar, a novel dual peroxisome proliferator-associated receptor α/γ agonist, on the treatment of post-LT NAFLD and metabolic burden. " 01/01/2018 - "In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH. " 07/08/2020 - "A long-term randomized controlled clinical trial is required to further establish the safety and efficacy of saroglitazar in the treatment of T2DM and NAFLD." 01/01/2020 - "Long-term randomized controlled clinical trial is required to further establish the safety and efficacy of saroglitazar in treatment of NAFLD." 10/01/2023 - "In this review, we comprehensively review the pharmacology, pre-clinical data, and clinical studies on saroglitazar usage in NAFLD and conduct a subgroup meta-analysis of studies focussing on the impact of saroglitazar on liver stiffness changes."
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2015 - "Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence." 01/01/2014 - "Saroglitazar appeared to be an effective and safe therapeutic option for improving hypertriglyceridemia in patients with type 2 diabetes mellitus." 01/01/2022 - "A prospective, interventional, pilot study was performed to study the safety and efficacy of saroglitazar in NAFLD patients having type 2 diabetes mellitus. " 07/08/2020 - "An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease." 01/09/2015 - "Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes."
4.	Hypertriglyceridemia 02/01/2014 - "Saroglitazar appeared to be an effective and safe therapeutic option for improving hypertriglyceridemia in patients with T2DM." 12/12/2019 - "The present case report illustrates the efficacy of Saroglitazar in reducing hypertriglyceridemia and liver stiffness as assessed by shear wave elastography." 01/01/2022 - "However, the effect of saroglitazar in patients with moderate to severe hypertriglyceridemia was not evaluated. " 11/01/2020 - "Letter to the editor in response to the article 'Efficacy and safety of Saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis' (Dutta et al.)." 11/01/2020 - "(2020) regarding 'efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis' (Dutta et al.)."
5.	Liver Cirrhosis (Hepatic Cirrhosis) 07/08/2020 - "The objective of this study was to observe the safety and effectiveness of saroglitazar, 4 mg once daily, in reducing glycemic parameters and liver fibrosis in type 2 diabetes mellitus (T2DM) patients with NAFLD. Method In this prospective observational study, we enrolled 30 patients with T2DM and NAFLD (primarily detected by ultrasonography (USG) of the abdomen) who were treated with saroglitazar, 4 mg once daily, and the follow-up data were available for six months after saroglitazar treatment. " 01/01/2022 - "Saroglitazar was found to show significant improvement in liver parameters in NAFLD patients with a significant reduction in liver fibrosis and triglycerides level." 12/12/2019 - "Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report." 01/01/2022 - "The aim of this study was to evaluate the effect of saroglitazar on liver function test, liver fibrosis score by FibroScan, lipid profiles, HbA1c in NAFLD patients with diabetic dyslipidemia in southern India. " 12/01/2019 - "The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin."

Related Drugs and Biologics

1.	Lipids
2.	Triglycerides (Triacylglycerol)
3.	Peroxisome Proliferator-Activated Receptors (PPAR)
4.	Fenofibrate (CiL)
5.	Pioglitazone (Actos)
6.	Atorvastatin (Lipitor)
7.	Adiponectin
8.	Tablets
9.	Sodium Glutamate (Accent)
10.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Glycemic Control
4.	Chemoprevention
5.	Liver Transplantation